PMID- 12445290
OWN - NLM
STAT- MEDLINE
DCOM- 20030616
LR  - 20190916
IS  - 0105-2896 (Print)
IS  - 0105-2896 (Linking)
VI  - 188
DP  - 2002 Oct
TI  - Towards patient-specific tumor antigen selection for vaccination.
PG  - 164-76
AB  - In this review, we discuss the possibilities for combining the power of molecular 
      analysis of the antigens expressed in a given individual tumor with the design of 
      a tailored vaccine containing defined antigens. Step 1 is a differential gene 
      expression analysis of tumor and corresponding normal tissue. Step 2 is the 
      analysis of human leukocyte antigen (HLA) ligands on tumor cells. Step 3 is data 
      mining with the aim to select those antigens that might be suitable for tumor 
      attack by the adaptive immune system. Step 4 is the on-the-spot clinical grade 
      production of the constituents of the patient tailored vaccine, e.g. peptides. 
      Step 5 is then vaccination and monitoring. Although it will not be possible to 
      cover all relevant antigens expressed in a tumor, the antigens that can be 
      identified with our present technical possibilities might be enough for improved 
      immunotherapy. The scope of the present review is to explore the possibilities 
      and the formidable technical and logistical challenge for such individual 
      patient-oriented antigen definition to be used for therapeutic immunization.
FAU - Rammensee, Hans-Georg
AU  - Rammensee HG
AD  - Department of Immunology, Institute for Cell Biology, University of Tubingen, 
      Tubingen, Germany. rammensee@uni-tuebingen.de
FAU - Weinschenk, Toni
AU  - Weinschenk T
FAU - Gouttefangeas, Cecile
AU  - Gouttefangeas C
FAU - Stevanovic, Stefan
AU  - Stevanovic S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Immunol Rev
JT  - Immunological reviews
JID - 7702118
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes, B-Lymphocyte)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA Antigens)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Algorithms
MH  - Amino Acid Motifs
MH  - Antigen Presentation
MH  - Antigens, Neoplasm/administration & dosage/*immunology
MH  - B-Lymphocytes/immunology
MH  - Cancer Vaccines/*immunology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Cytotoxicity, Immunologic
MH  - Databases, Factual
MH  - Epitopes, B-Lymphocyte/immunology
MH  - Epitopes, T-Lymphocyte/immunology
MH  - HLA Antigens/immunology
MH  - Humans
MH  - *Immunotherapy, Active
MH  - Neoplasms/*immunology/therapy
MH  - Receptors, Antigen, T-Cell/immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - T-Lymphocytes, Helper-Inducer/immunology
MH  - Vaccines, Subunit/immunology/therapeutic use
RF  - 128
EDAT- 2002/11/26 04:00
MHDA- 2003/06/17 05:00
CRDT- 2002/11/26 04:00
PHST- 2002/11/26 04:00 [pubmed]
PHST- 2003/06/17 05:00 [medline]
PHST- 2002/11/26 04:00 [entrez]
AID - imr18815 [pii]
AID - 10.1034/j.1600-065x.2002.18815.x [doi]
PST - ppublish
SO  - Immunol Rev. 2002 Oct;188:164-76. doi: 10.1034/j.1600-065x.2002.18815.x.